1.

Judul : Response to Neoadjuvant Therapy and Long Term Survival in

Patients With TNBC
Author : Cornelia Liedtke. et al. 2008
Background : Compare response to neoadjuvant chemotherapy and
survival between pateints with TNBC and non-TNBC
Patients & Method : 1.118 pasien stage I-III BC menerima NAC
Regimen :
- FAC / FEC / AC : pCR TNBC = 20% (n=14)
- TFAC / TFEC : pCR TNBC = 35 % (n=28) -> weekly / once every 3
weeks packlitaxel/docetaxel followed by FAC/FEC
- Single Agent Taxane : not significance

2. Judul : The Use of neoadjuvant platinum based chemotherapy in locally

advanced breast cancer that is triple negative : retrospective analysis of
144 patients
Judith Hurley. Et al. 2013
Background : mengevaluasi pCR, PFS, dan OS pada pasien dengan TNBC
yang diterapi dengan Neoadjuvant platinum based chemotherapy
Method : penelitian retrospektif 144 wanita TNBC mendapat terapi
neoadjuvant platinum based chemotherapy cisplatin based vs carboplatin
based
Hasil :
- Cisplatin based : 39 (40,2%) pCR breast dan 66 (68%) pCR axilla
- Carboplatin based : 12 (25,5%) pCR breast dan 21 (44,7%) pCR axilla
3. Judul : Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy
for TNBC : safety dat from a phase III randomized open label trial
Author : Yuan P
Background : Beberapa penelitian menunjukkan TNBC sensitif terhadap
cispalatin dan carboplatin dengan dasar disfungsi BRCA1 dan
berhubungan dengan DNA repair-defect, namun data mengenai adjuvant
setting masih terbatas
Konklusi : EC-T dan TP sebagai ajuvan aman dan tolerable. TP memilki
keuntungan less grade II/IV alopecia and leukopenia.
4. Judul : Docetaxel followed by fluorouracil/epirubicin/ cyclophosphamide as
NAC for patients with primary breast cancer
Author : Iwat H. Et al. 2011
Background : multicenter, open label, single-arm, phase II study assesd
the efficacy of a Neoadjuvant chemotherapy with docetaxel (75 mg/m(2)
q3w) followed by 5-fluorouracil 500 mg/m(2), epirubcin 100 mg/m(2) and
cyclophosphamide 500 mg/m2 q3 minggu pada pasien early stage breast
cancer.
Results : 23% pCR, 6% nearly CR. 64% mengalami clinical response rate
setelah pemberian docetaxel. Dan menjadi 79% setelah pemberian FEC.
5. Judul Long term survival of advancerd TNBC dengan dose intense
ciclophosphamide / anthracycline neoadjuvant regimen
S Giacchetti 2014

Background : TNBC memberikan respon terhadap Neoadjuvant

chemotherapy namun outcome dari TNBC sangat buruk. Pasien LABC
TNBC diterapi dengan golongan cyclophosphamide-anthracycline
deibandingkan dengan ACT
Results : kedua regimen memiliki pCR yang equivalen.